PMID- 33236505
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 75
IP  - 4
DP  - 2021 Apr
TI  - Impact of metformin therapy on health-related quality of life outcomes in 
      tuberculosis patients with diabetes mellitus in India: A prospective study.
PG  - e13864
LID - 10.1111/ijcp.13864 [doi]
AB  - OBJECTIVE: To assess the impact of metformin use on health-related quality of 
      life (HRQoL) in tuberculosis (TB) patients who are presented with type 2 diabetes 
      mellitus (T2DM). METHODOLOGY: In this community-based prospective study, TB 
      patients attending Hakeem Abdul Hameed Centenary Hospital, New Delhi (India) and 
      had comorbidity of T2DM between April 2018 and July 2019 were enrolled. Patients 
      were divided into metformin users and metformin non-users on the basis of the 
      presence of metformin in their routine as antidiabetic drug(s). HRQoL was 
      determined using a validated TB-specific tool (Dhingra and Rajpal-12 scale ie, 
      DR-12) consists of symptom and socio-psychological and exercise adaptation 
      domains. The HRQoL scores were compared at pretreatment (1st visit), end of 
      intensive phase (2nd visit) and end of treatment (3rd visit) between the two 
      groups. RESULTS: A total of 120 patients were enrolled, of which 24 were excluded 
      as they did not respond at follow-up visits. Among the metformin users (n = 48) 
      the mean age of patients was 47.56 years and 62.50% was males. Among the 
      metformin non-users (n = 48), the mean age of patients was 49.02 years and 54.10% 
      was males. The baseline characteristics were similar in both groups except for 
      the substance used history (P = .025), literacy level (P = .048) and BMI 
      (P = .028). Metformin users demonstrated significant improvement in symptom 
      scores (2nd visit: P < .001; 3rd visit: P = .001) and socio-psychological and 
      exercise adaptation scores (2nd visit: P < .0001; 3rd visit: P < .0001) as 
      compared with metformin non-users at 2nd visit and 3rd visit. Overall, scores 
      were also found to be significantly improved in metformin users (2nd visit: 
      P < .001; 3rd visit: P = .001). CONCLUSION: Metformin therapy exerted favourable 
      effects on HRQoL in patients with TB and T2DM and can be recommended as an 
      adjuvant antitubercular drug in TB patients with co-morbidity of T2DM, unless 
      contraindicated.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Mishra, Ritu
AU  - Mishra R
AD  - Department of Pharmacology, School of Pharmaceutical Education and Research, 
      Jamia Hamdard, New Delhi, India.
FAU - Krishan, Shri
AU  - Krishan S
AD  - Department of Drug Safety and Pharmacovigilance, Syneos Health, Gurgaon, India.
FAU - Siddiqui, Ali Nasir
AU  - Siddiqui AN
AD  - Department of Pharmaceutical Medicine, School of Pharmaceutical Education and 
      Research, Jamia Hamdard, New Delhi, India.
FAU - Kapur, Prem
AU  - Kapur P
AD  - Department of Medicine, Hamdard Institute of Medical Sciences and Research & 
      Hakeem Abdul Hameed Centenary Hospital, Jamia Hamdard, New Delhi, India.
FAU - Khayyam, Khalid Umer
AU  - Khayyam KU
AD  - Department of Epidemiology & Public Health, National Institute of Tuberculosis & 
      Respiratory Diseases, New Delhi, India.
FAU - Rai, Pradeep Kumar
AU  - Rai PK
AD  - Department of Life Sciences, BD Biosciences, Gurgaon, India.
FAU - Sharma, Manju
AU  - Sharma M
AUID- ORCID: 0000-0003-4013-6626
AD  - Department of Pharmacology, School of Pharmaceutical Education and Research, 
      Jamia Hamdard, New Delhi, India.
LA  - eng
GR  - IF-160196/Department of Science and Technology, Philippines/
GR  - IF-160196/Department of Science and Technology, India/
PT  - Journal Article
DEP - 20201210
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - India/epidemiology
MH  - Male
MH  - *Metformin/therapeutic use
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - *Tuberculosis
OTO - NOTNLM
OT  - diabetes
OT  - drug repositioning
OT  - health-related quality of life
OT  - metformin
OT  - tuberculosis
EDAT- 2020/11/26 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/11/25 05:52
PHST- 2020/09/02 00:00 [revised]
PHST- 2020/06/17 00:00 [received]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/11/25 05:52 [entrez]
AID - 10.1111/ijcp.13864 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2021 Apr;75(4):e13864. doi: 10.1111/ijcp.13864. Epub 2020 Dec 
      10.